{"ticker": {"uuid": "ba85fc2a-c03e-495a-b560-6f25e5dc49d8", "symbol": "MRVI", "name": "Maravai Lifesciences Holdings\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Maravai LifeSciences(MRVI) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwJBVV95cUxQVDJUajB5UGM0LUxPc0xzRjBuRklXQm0yS083dHhLakRYRllGRjZLYWFKWlZrWHZydnlPY3I1QzhINVlfbEtrNDJ3U2MwT3ZNVGNNRTlhcnozWjBNV1FpTlB4bUpiMVJaY3Y0aldwRUpLaWtYbHB6QlFFRkt0VEdJZFhyRy1VUE9uNHAwa2hPN1dINEJpX1lIOUZSU0l6YWlxMFpqUkh0eHRVZ0ZDaW16X0dRRVBxQmpVeTBNYTA4SWl3dGZBdTlKaG5qV0lIbmxPN0FmankxUnUxUXpST0hSQ3VCWXZEZlprZ2FJRVNsQTkyRjg4MlBuNVA5OTZZWkt5Y0x2Y3M4czV1UktkWThsNFVLSmo5NWwxN0lxcW1rY1BPc01qQjJSZVR4SnJxUk00X1BGMndNZS1PWWJDTzE4THlYbw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T12:27:47+00:00", "published_display": "13 Jul 2026 12:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Maravai Lifesciences Holdings Inc For: 10 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNb2dSN19xdXcwbXZmZWdqNDhMclBsbk1vbHFzWTF3X0xZdnFXdmNrSTl3Z3pRZmZjMnpiUHFYM254eXB5NWE1YVhMM1o1VmtKLXQyRUtWVC1PeGpkVzhTTkUta2ZHT0FMRE12Zk9IckJlbWlhVC1udm5lUXAwZTJDaEh5MGJvZkJzcHpjZEg3NGVTeTlqX2hteTlEdHdIZWtYNUVDTTVDUWxrVm5lUFpCb3FR?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T22:26:57+00:00", "published_display": "10 Jul 2026 22:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai Lifesciences (MRVI) CEO reports 29,250-share tax withholding event", "summary": "Maravai Lifesciences (MRVI) CEO Bernd Brust reported the withholding of 29,250 Class A shares to cover tax obligations related to the vesting of restricted stock units. This was a non-open-market, tax-related disposition, not a sale. After this transaction, Brust directly holds 1", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-cc21cece2be3.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:10:29", "published_display": "10 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Maravai LifeSciences Holdings, Inc. \u2013 NASDAQ:MRVI", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxObnFIenpxT2h5SGNtVUc3cWc3V0lYbVNrZnZMdDlqOWVuY0dPX3RZQUdGU1c2OF9tMi1JQWVDeHE2M01WeHlkclljU0hRWjB0ajRvVlRibVZ5a1R6N0hlanROUXJSZEREaEVaX2lCdjJVd0VDbGxUTU1fVV9mVmhENGJIVjY2UFUyZ2JuVnN1eEpvLXdUMDhUY3pwdmE?oc=5", "source_name": "TradingView", "published_at": "2026-07-04T11:49:05+00:00", "published_display": "04 Jul 2026 11:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) CFO has 65,584 shares withheld for RSU tax", "summary": "Maravai Lifesciences Holdings CFO Rajesh Asarpota reported a routine disposition of 65,584 Class A Common Stock shares. These shares were withheld at $6.39 each to cover tax obligations upon the vesting of restricted stock unit awards. As a result, Asarpota now directly holds 434", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-8f1e0e9688a2.html", "source_name": "Stock Titan", "published_at": "2026-07-02T01:10:05", "published_display": "02 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (MRVI) Slips 3.83% as Stock Nears Critical Support Area - Watchlist Stock Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQM19rN2dIeldzekRmMWZETlc1QWVPUlUyMzh3dTNndU5HWXRFVGpCVXJ4RXBTYmhmcko5eFQzVUFpT1h1RmRzSFZ1bU43bGJBMFlNVWhkM3plYU85SmQ3U3ZhWkpmWnM5WDRnZjFqU05iUnN5ZFNtcEpPdUR5ZElYQW9ZeEU5dEx2QTFoLWdXM1dUTEFiSGp1TUM0Ui1QbGNLR2FadTdOcFRxUElZaWxQeHJBb216YTJYMGVJ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Maravai Lifesciences Holdings, Inc. Class A Stocks", "summary": "This article provides a list of Exchange Traded Funds (ETFs) that hold Maravai Lifesciences Holdings, Inc. Class A stocks, sorted by market value. It details various ETFs including their market value, weight, issuer, management style, focus, expense ratio, AUM, price change, rela", "url": "https://www.tradingview.com/symbols/SWB-MAR/etfs/", "source_name": "TradingView", "published_at": "2026-06-30T02:39:02", "published_display": "30 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium Management reports >5% stake then falls below 5% in MRVI (MRVI)", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reported acquiring over a 5% beneficial ownership stake in Maravai LifeSciences Holdings, Inc. (MRVI) on June 23, 2026, via a Schedule 13G filing. However, by the filing date, they had ceased to b", "url": "https://www.stocktitan.net/sec-filings/MRVI/schedule-13g-maravai-lifesciences-holdings-inc-passive-investment-dis-68b50e5a957e.html", "source_name": "Stock Titan", "published_at": "2026-06-30T02:36:02", "published_display": "30 Jun 2026 02:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Maravai Lifesciences Holdings, Inc. Class A \u2013 SWB:MAR", "summary": "This page displays the \"Price to earnings forward\" metric for Maravai Lifesciences Holdings, Inc. Class A, traded on the Stuttgart Stock Exchange under the symbol MAR. The primary content consists of various navigation links and footer information from the TradingView platform, w", "url": "https://www.tradingview.com/symbols/SWB-MAR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:12:23", "published_display": "29 Jun 2026 03:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MAR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Maravai Lifesciences Holdings, Inc. (MAR) stock for 2027, based on analyst opinions. It details the company's financial performance, including recent earnings and revenue, and addresses frequently asked questions about its sto", "url": "https://www.tradingview.com/symbols/SWB-MAR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T00:09:07", "published_display": "27 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai Lifesciences Holdings, Inc. Class A Actuals & Estimates (NASDAQ:MRVI)", "summary": "This article provides key financial metrics and analyst forecasts for Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI). It details the company's stock performance, market capitalization, earnings, revenue, and other financial data, highlighting recent fluctuations and future es", "url": "https://www.tradingview.com/symbols/NASDAQ-MRVI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T00:39:56", "published_display": "26 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium (MRVI) reports 7.32M shared stake, 4.96% as of Jun 16, 2026", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander filed a Schedule 13G for Maravai LifeSciences Holdings, Inc. (MRVI). The filing indicates shared beneficial ownership of 7,323,520 Class A common shares, representing 4.96% as of June 16, 2026. Al", "url": "https://www.stocktitan.net/sec-filings/MRVI/schedule-13g-maravai-lifesciences-holdings-inc-passive-investment-dis-44d9a9aeaeb1.html", "source_name": "Stock Titan", "published_at": "2026-06-23T22:52:31", "published_display": "23 Jun 2026 22:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (MRVI) Holds Steady as Shares Consolidate Near Support Levels - Fibonacci Retracement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPdmlkY3JJTEFKUTZnQk1Mc1N2MVZTQ0xKakdYMVdmWnNYUVRROHZHYmEzY2VNcmRrQ2xCYW0xa2RhdkI3bjFKMlozaTBGdzk0OTQ4cGRuUDJRXzdXZlVpVzVoS1ZFcUhfT3FQblYzVW1HeTVoTTVEbDZsdXR4c2tybEdKVkV0dzZZSXRHOUxCcXVaaGx6OFd4TWdBRXRlNFdhQlM5YWpWS1VGdTU2SVdoeGxheHNtMlRTNHFEWERTVXpzUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai Lifesciences Unit TriLink Opens Enzyme Manufacturing Facility in Florida", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/maravai-lifesciences-unit-trilink-opens-140710740.html", "source_name": "MT Newswires", "published_at": "2026-06-16T14:07:10+00:00", "published_display": "16 Jun 2026 14:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences general counsel Oreshack sells $253,999 shares", "summary": "Kurt Oreshack, General Counsel at Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), recently sold 50,000 shares of the company's Class A Common Stock for approximately $253,999. These sales were conducted under a Rule 10b5-1 trading plan and occurred on June 9 and 10, 2026, with", "url": "https://m.uk.investing.com/news/insider-trading-news/maravai-lifesciences-general-counsel-oreshack-sells-253999-shares-93CH-4722722?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-11T00:10:27", "published_display": "11 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai Lifesciences Holdings Insider Sold Shares Worth $254,000, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/maravai-lifesciences-holdings-insider-sold-211654257.html", "source_name": "MT Newswires", "published_at": "2026-06-10T21:16:54+00:00", "published_display": "10 Jun 2026 21:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai Lifesciences director gifts 92,586 shares | MRVI Insider Trading", "summary": "Maravai Lifesciences Holdings director Gregory T. Lucier reported gifting 92,586 shares of Class A common stock on June 9, 2026. The gifts were made in two bona fide transfers of 46,293 shares each at $0.00 per share. Following these transactions, Lucier directly holds 155,123 sh", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-9a04c286903c.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:27", "published_display": "10 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (NASDAQ: MRVI) General Counsel sells 50,000 shares under 10b5-1 plan", "summary": "Maravai Lifesciences' General Counsel, Kurt Oreshack, sold a total of 50,000 shares of Class A Common Stock through open-market transactions on June 9 and June 10, 2026. These sales, totaling $254,000, were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 1", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-a398504aade9.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:27", "published_display": "10 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MRVI SEC Filings - Maravai Lifesciences Holdings, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Maravai Lifesciences Holdings (MRVI) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms. Recent filings detail director equity awards, a CFO transition, an", "url": "https://www.stocktitan.net/sec-filings/MRVI/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:21", "published_display": "10 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kurt Oreshack notifies sale of 25,000 MRVI Class A shares (NASDAQ: MRVI)", "summary": "Kurt Oreshack has filed a Form 144 to sell 25,000 Class A shares of Maravai Lifesciences Holdings, Inc. (MRVI). The filing, dated June 10, 2026, indicates an aggregate amount of $127,500.00 and notes that the securities originated from Restricted Stock Vesting on January 15, 2025", "url": "https://www.stocktitan.net/sec-filings/MRVI/144-maravai-lifesciences-holdings-inc-sec-filing-ad1cf470b617.html", "source_name": "Stock Titan", "published_at": "2026-06-10T19:39:59", "published_display": "10 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) brokered sale notice: 25,000 Class A shares via Fidelity", "summary": "Maravai LifeSciences (MRVI) has filed a Form 144, indicating an intent to sell 25,000 Class A common shares through Fidelity Brokerage Services LLC on NASDAQ. The filing details previous acquisitions of these shares through restricted stock vesting and ESPP purchases. This is a r", "url": "https://www.stocktitan.net/sec-filings/MRVI/144-maravai-lifesciences-holdings-inc-sec-filing-e5fd5a4cfd4a.html", "source_name": "Stock Titan", "published_at": "2026-06-09T14:39:38", "published_display": "09 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOdUV6ZnRYMFJSazNYZGVaOEtxOF9rb0djQ0xfU0FfLW9PY0pQYXFHdGJsbTBQVkNiMk45d3ZfT1dXdDBfekxCLWNCckxEMkMxRVltU0w5TW01T0FOVjFGQjBCQlhybm5UTlJCaXREbGFNeWYxamE4NDRsN2s5VDc4a0x3ZEV2SUpyLVVCU1NFWHE3bUl6VmZvUmxpQ2dmUEpEQTJ6Yw?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Refinances Credit Agreement, Extends Maturity to 2032", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/maravai-lifesciences-refinances-credit-agreement-130223268.html", "source_name": "MT Newswires", "published_at": "2026-06-03T13:02:23+00:00", "published_display": "03 Jun 2026 13:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/maravai-lifesciences-announces-refinancing-credit-123000426.html", "source_name": "Business Wire", "published_at": "2026-06-03T12:30:00+00:00", "published_display": "03 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (MRVI) Secures New $150M Credit Facility", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdkFnNXJyUmw5cmw3MWU5Z1JaMUc1MmxoOF8tVmNmd2QwOVVEWlRPYmxULUdUbHhfNXFNYzRrSW1LdzNsVVRQOTJycjZzYWxFSVhNdDR4ZVJIck1XaFd4TGxfM25jX2N3bU4wc1JMTEZjZ3hSd3FvaW40eGhERUdOdG1yYjJWOHh2ZUFhTXlkYTJ3X3FtT3d4c0JhNW11ZHBGVVhrX1h0WUJ5ZlZEWnc?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (MRVI) shareholders approve directors, auditor and pay at 2026 meeting", "summary": "Maravai LifeSciences Holdings, Inc. announced the results of its 2026 Annual Meeting of Shareholders. During the meeting, shareholders elected three directors to three-year terms, ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026, and ap", "url": "https://www.stocktitan.net/sec-filings/MRVI/8-k-maravai-lifesciences-holdings-inc-reports-material-event-188be1450a75.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:39:30", "published_display": "29 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) director granted 46,293 restricted stock units", "summary": "Maravai LifeSciences Holdings director Gregory T. Lucier was granted 46,293 restricted stock units of Class A Common Stock on May 26, 2026, with a grant price of $0.00. This award, under the 2020 Omnibus Incentive Plan, vests in full on the earlier of one year from the grant date", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-a-maravai-lifesciences-holdings-inc-amended-insider-trading-ac-c1d9ba1afff0.html", "source_name": "Stock Titan", "published_at": "2026-05-29T00:39:31", "published_display": "29 May 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) director Susannah Gray receives 46,293-share stock unit award", "summary": "Maravai LifeSciences Holdings, Inc. director Susannah Gray was granted 46,293 restricted stock units (RSUs) of Class A Common Stock. This award, made under the 2020 Omnibus Incentive Plan, increased her direct holdings to 216,200 shares. The RSUs will vest in full after one year ", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-6847ba982f28.html", "source_name": "Stock Titan", "published_at": "2026-05-28T22:10:56", "published_display": "28 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading Activity", "summary": "Maravai LifeSciences (MRVI) director Gregory T. Lucier reported an acquisition of 46,293 shares of Class A Common Stock through restricted stock units (RSUs) at a reference price of $4.38 per share. This RSU award, granted under the 2020 Omnibus Incentive Plan, vests fully on the", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-9deefc0707d3.html", "source_name": "Stock Titan", "published_at": "2026-05-28T22:10:56", "published_display": "28 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (MRVI) director receives 46,293-share RSU award", "summary": "MARAVAI LIFESCIENCES HOLDINGS, INC. director R. Andrew Eckert was granted 46,293 restricted stock units (RSUs) of Class A common stock as an equity compensation award on May 26, 2026. These RSUs were issued at no cost and will vest fully on the earlier of one year from the grant ", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-2bd4741c3ea9.html", "source_name": "Stock Titan", "published_at": "2026-05-28T22:10:56", "published_display": "28 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU grant to GTCR-affiliated entity via Maravai (MRVI) director", "summary": "Maravai LifeSciences Holdings director Sean Laurence Cunningham was awarded a 46,293-share Restricted Stock Unit (RSU) grant, vesting on the earlier of one year from May 26, 2026, or the company's 2027 annual meeting. These securities are held for the benefit of a GTCR-affiliated", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-bb371be12755.html", "source_name": "Stock Titan", "published_at": "2026-05-28T22:10:56", "published_display": "28 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) director Mihas receives 46,293 RSUs held for GTCR-affiliated entity", "summary": "Maravai LifeSciences Holdings, Inc. director Constantine S. Mihas was granted 46,293 restricted stock units (RSUs) of Class A common stock on May 26, 2026, under the company's 2020 Omnibus Incentive Plan. These RSUs vest fully on the earlier of one year from the grant date or the", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-d7bc09b75dd0.html", "source_name": "Stock Titan", "published_at": "2026-05-28T22:10:56", "published_display": "28 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) director awarded 46,293 RSUs in equity grant", "summary": "Maravai LifeSciences (MRVI) director John A. DeFord was granted 46,293 restricted stock units (RSUs) on May 26, 2026. These RSUs, awarded under the company\u2019s 2020 Omnibus Incentive Plan, will vest fully on the earlier of one year from the grant date or the 2027 annual stockholder", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-193dbde019f4.html", "source_name": "Stock Titan", "published_at": "2026-05-28T22:10:56", "published_display": "28 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai Lifesciences (NASDAQ: MRVI) counsel gets 776 ESPP shares", "summary": "Maravai LifeSciences Holdings, Inc.'s General Counsel, Kurt Oreshack, acquired 776 shares of Class A Common Stock at $2.84 per share through the company\u2019s 2020 Employee Stock Purchase Plan. This transaction, exempt under Rule 16b-3, increased Oreshack's direct holdings to 385,767", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-fcc6a30e595b.html", "source_name": "Stock Titan", "published_at": "2026-05-22T23:09:27", "published_display": "22 May 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) officer granted 5,006 ESPP shares at $1.79", "summary": "Maravai LifeSciences Holdings insider Christine Dolan acquired 5,006 shares of Class A common stock at $1.79 per share through the company's 2020 Employee Stock Purchase Plan. This transaction, exempt under Rule 16b-3, increases Dolan's direct holdings to 425,318 shares and is co", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-1c6b8dd8d00d.html", "source_name": "Stock Titan", "published_at": "2026-05-22T23:09:27", "published_display": "22 May 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQYzh6Tmw3VHNoNk5Xelg1Sk1rNmRpQnVTbm96Wm43UjBWTENqQTdYR1F6bFMtbWhvOWl2alV1cFdJSXFYVTVmZ29JSkFmc0dfQmpHWnpVdHE5OFlUejRwblJ6Vl9wT0N2V3IyejdOS2RXbXVyYzd2aG95VWdsaVFHZDFsNkJHT2VQMF9tV1RhY2llQklGaTlkLW55R24zQV8yWl9TSnFRR2twVjJhYlZIOXdZWnpzb1luMkE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Q1 Turnaround Spurs Rethink Of CleanCap Driven Outlook", "summary": "Maravai LifeSciences Holdings (NasdaqGS:MRVI) reported a significant Q1 2026 turnaround with a 41% revenue jump, narrowed net loss, and positive Adjusted EBITDA, driven by a large CleanCap vaccine order and debt reduction. The strong performance has led to a re-evaluation of the ", "url": "https://www.sahmcapital.com/news/content/maravai-lifesciences-q1-turnaround-spurs-rethink-of-cleancap-driven-outlook-2026-05-14", "source_name": "Sahm", "published_at": "2026-05-15T19:10:09", "published_display": "15 May 2026 19:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 West Capital Amends 13G, Holds 7.26M Shares in Maravai (MRVI)", "summary": "12 West Capital Management and Joel Ramin have filed an amended 13G, reporting beneficial ownership of 7,260,195 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI), which represents a 4.9% stake in the company. This percentage is calculated based on 146,383", "url": "https://www.stocktitan.net/sec-filings/MRVI/schedule-13g-a-maravai-lifesciences-holdings-inc-amended-passive-inve-a778da77a7e3.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:40:04", "published_display": "15 May 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 Guidance", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/maravai-lifesciences-mrvi-narrative-shifting-012919067.html", "source_name": "Simply Wall St.", "published_at": "2026-05-15T01:29:19+00:00", "published_display": "15 May 2026 01:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stuart Feldman-led group reports 9.21% stake in Maravai (MRVI)", "summary": "A group led by Stuart Feldman has filed an amended Schedule 13G/A, disclosing a passive beneficial ownership of 13,488,799 shares of Maravai LifeSciences Holdings, Inc. Class A common stock, representing 9.21% of the class. Stuart Feldman individually holds 10,337,680 shares (7.0", "url": "https://www.stocktitan.net/sec-filings/MRVI/schedule-13g-a-maravai-lifesciences-holdings-inc-amended-passive-inve-b5a0edde9804.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:40:02", "published_display": "14 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Millennium group lists 4.9% holding in Maravai (NASDAQ: MRVI) on 13G", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G reporting a shared voting and dispositive power over 7,228,864 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock, which represents a 4.9% stake. The fili", "url": "https://www.stocktitan.net/sec-filings/MRVI/schedule-13g-maravai-lifesciences-holdings-inc-passive-investment-dis-2c343564da89.html", "source_name": "Stock Titan", "published_at": "2026-05-13T05:40:49", "published_display": "13 May 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Maravai (MRVI) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/9ce5ab11-8fd7-3ac3-b423-d589e116c563/maravai-%28mrvi%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-09T20:35:31+00:00", "published_display": "09 May 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (NASDAQ: MRVI) boosts Q1 revenue, cuts debt", "summary": "Maravai LifeSciences reported significantly improved financial results for Q1 2026, with revenue increasing by 40.5% to $65.8 million, driven largely by its TriLink segment and $14.3 million in CleanCap\u00ae COVID-19 vaccine orders. The net loss narrowed to $6.4 million, and Adjusted", "url": "https://www.stocktitan.net/sec-filings/MRVI/10-q-maravai-lifesciences-holdings-inc-quarterly-earnings-report-2721b0d7cbe9.html", "source_name": "Stock Titan", "published_at": "2026-05-09T18:09:14", "published_display": "09 May 2026 18:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Holdings, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/c1ba3b95-75ec-390b-925d-7c3e9c5e00f3/maravai-lifesciences.html", "source_name": "Moby", "published_at": "2026-05-08T12:30:00+00:00", "published_display": "08 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deutsche Bank Adjusts Maravai Lifesciences Price Target to $6 From $4.50, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/deutsche-bank-adjusts-maravai-lifesciences-122255168.html", "source_name": "MT Newswires", "published_at": "2026-05-08T12:22:55+00:00", "published_display": "08 May 2026 12:22", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Holdings, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:MRVI) 2026-05-07", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaklXcE4wYUs2UWJzUGZEcUZtZ3hFQUl4RWlGMkF1NVJoM1dHWEtDMDhEcnF2RGVaYzRvMjk4NzZhOGZkenBXbVVQdXo3Tm5RRUdvLUlDOWRCOEp6MXlocEtCRnZmMjdoZzFkcUg2QVZqTkFTakJQczNSdXhzbWJwWmR5M3hvdzQ0WGtFSTl0SzRTRlhSeTBmVkpBUDFFWk0tUzBpTERzWXFJNXhNc19QdGx2ZEJSZ0RF?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWEp3YzZMemQ3bkFBSkZOdW1oc18tUEJrV21GUzBURmNIcWdQVHp1cnJkYWpQdE1ndEFtRnMyU3NYbThBSE1XZWNYZGw5emdtUXdjMG5QY3pqMjBiT3JPQTBWRjBwOEc5MXF4SW5EQm91R3UweEdlY1dPdG84LWM1Vi1STU11UVhXRnc2eVFWdm1LU2dPZDRfc19PZmFZM29yZjNFbFJLMmlaYmM?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxORzBTYmpmaVo5Ri0zWjZGX21zN3F2N3lTVXBDNnp5cVJuTlJoM3YwSUVCNEZkWVhJU0VDS1NJcXp3dTYzNUhfUElXeVNZakxiWFVwZVZZOGNFM2prZVBIU1Q5ZFNSQTZEWXJocXNKNU1weHhpOEVoV1AzYVoyS2h3Z3dYM2xqcC14eXBDQmpPcU9rUDR1ejRhWmlEbGNLcDJlYUZYMA?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Maravai LifeSciences (MRVI) Carrying Moderately Bullish Sentiment Despite Options-Linked Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQQ2hNaHVESGlacDkyRzI5SkRfZ2VreDd5dWJZV3Mwc09mVW8wNGttNEtkeGRjZm9GRXE2MklpUU44MFlGaVEzOGV5SEVKeFQ5RVpoQ2FIdXJNVEpGVk5FLWphT0E5Y2wyWG5HQ1ZITjZvNHdxNUxWMVVuSV9lTEg5bTVmaFlKemlaR2JiX29Nc2hsNUFtYjFQX2E5WFRvR3lnclFsS3ZOYVBxdTJ1eXFV?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Maravai LifeSciences (MRVI) Story Is Shifting As Analysts Rework Fair Value Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNcFBCcW9XZ0tveU1xbnZoam8tcmhjQjRzR2VnRGtEUEhVVk5hSDR6Y191MlRJbUYtUXNPWW5ZUlhDZ25ITEpyaUpPdDNCaHczeU9KdWxXTWdvRHVibFZ5ekQzRUVvaFNfdmlEYUVWWm95dXc3Z0hrSkhtcGFJMm5rbjlPeVB6d1c1bUh3c3BmS0drLXFjYy1DTEJEb3ZRRHlhR1l3REFPOWo?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Maravai LifeSciences Holdings (NASDAQ:MRVI shareholders incur further losses as stock declines 11% this week, taking five-year losses to 90%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Maravai LifeSciences Holdings (NASDAQ:MRVI) Using Too Much Debt?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-15T08:00:00+00:00", "published_display": "15 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Maravai LifeSciences(MRVI) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwJBVV95cUxQVDJUajB5UGM0LUxPc0xzRjBuRklXQm0yS083dHhLakRYRllGRjZLYWFKWlZrWHZydnlPY3I1QzhINVlfbEtrNDJ3U2MwT3ZNVGNNRTlhcnozWjBNV1FpTlB4bUpiMVJaY3Y0aldwRUpLaWtYbHB6QlFFRkt0VEdJZFhyRy1VUE9uNHAwa2hPN1dINEJpX1lIOUZSU0l6YWlxMFpqUkh0eHRVZ0ZDaW16X0dRRVBxQmpVeTBNYTA4SWl3dGZBdTlKaG5qV0lIbmxPN0FmankxUnUxUXpST0hSQ3VCWXZEZlprZ2FJRVNsQTkyRjg4MlBuNVA5OTZZWkt5Y0x2Y3M4czV1UktkWThsNFVLSmo5NWwxN0lxcW1rY1BPc01qQjJSZVR4SnJxUk00X1BGMndNZS1PWWJDTzE4THlYbw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T12:27:47+00:00", "published_display": "13 Jul 2026 12:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Maravai Lifesciences Holdings Inc For: 10 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNb2dSN19xdXcwbXZmZWdqNDhMclBsbk1vbHFzWTF3X0xZdnFXdmNrSTl3Z3pRZmZjMnpiUHFYM254eXB5NWE1YVhMM1o1VmtKLXQyRUtWVC1PeGpkVzhTTkUta2ZHT0FMRE12Zk9IckJlbWlhVC1udm5lUXAwZTJDaEh5MGJvZkJzcHpjZEg3NGVTeTlqX2hteTlEdHdIZWtYNUVDTTVDUWxrVm5lUFpCb3FR?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T22:26:57+00:00", "published_display": "10 Jul 2026 22:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai Lifesciences (MRVI) CEO reports 29,250-share tax withholding event", "summary": "Maravai Lifesciences (MRVI) CEO Bernd Brust reported the withholding of 29,250 Class A shares to cover tax obligations related to the vesting of restricted stock units. This was a non-open-market, tax-related disposition, not a sale. After this transaction, Brust directly holds 1", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-cc21cece2be3.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:10:29", "published_display": "10 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Maravai LifeSciences Holdings, Inc. \u2013 NASDAQ:MRVI", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxObnFIenpxT2h5SGNtVUc3cWc3V0lYbVNrZnZMdDlqOWVuY0dPX3RZQUdGU1c2OF9tMi1JQWVDeHE2M01WeHlkclljU0hRWjB0ajRvVlRibVZ5a1R6N0hlanROUXJSZEREaEVaX2lCdjJVd0VDbGxUTU1fVV9mVmhENGJIVjY2UFUyZ2JuVnN1eEpvLXdUMDhUY3pwdmE?oc=5", "source_name": "TradingView", "published_at": "2026-07-04T11:49:05+00:00", "published_display": "04 Jul 2026 11:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) CFO has 65,584 shares withheld for RSU tax", "summary": "Maravai Lifesciences Holdings CFO Rajesh Asarpota reported a routine disposition of 65,584 Class A Common Stock shares. These shares were withheld at $6.39 each to cover tax obligations upon the vesting of restricted stock unit awards. As a result, Asarpota now directly holds 434", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-8f1e0e9688a2.html", "source_name": "Stock Titan", "published_at": "2026-07-02T01:10:05", "published_display": "02 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (MRVI) Slips 3.83% as Stock Nears Critical Support Area - Watchlist Stock Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQM19rN2dIeldzekRmMWZETlc1QWVPUlUyMzh3dTNndU5HWXRFVGpCVXJ4RXBTYmhmcko5eFQzVUFpT1h1RmRzSFZ1bU43bGJBMFlNVWhkM3plYU85SmQ3U3ZhWkpmWnM5WDRnZjFqU05iUnN5ZFNtcEpPdUR5ZElYQW9ZeEU5dEx2QTFoLWdXM1dUTEFiSGp1TUM0Ui1QbGNLR2FadTdOcFRxUElZaWxQeHJBb216YTJYMGVJ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Maravai Lifesciences Holdings, Inc. Class A Stocks", "summary": "This article provides a list of Exchange Traded Funds (ETFs) that hold Maravai Lifesciences Holdings, Inc. Class A stocks, sorted by market value. It details various ETFs including their market value, weight, issuer, management style, focus, expense ratio, AUM, price change, rela", "url": "https://www.tradingview.com/symbols/SWB-MAR/etfs/", "source_name": "TradingView", "published_at": "2026-06-30T02:39:02", "published_display": "30 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium Management reports >5% stake then falls below 5% in MRVI (MRVI)", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander reported acquiring over a 5% beneficial ownership stake in Maravai LifeSciences Holdings, Inc. (MRVI) on June 23, 2026, via a Schedule 13G filing. However, by the filing date, they had ceased to b", "url": "https://www.stocktitan.net/sec-filings/MRVI/schedule-13g-maravai-lifesciences-holdings-inc-passive-investment-dis-68b50e5a957e.html", "source_name": "Stock Titan", "published_at": "2026-06-30T02:36:02", "published_display": "30 Jun 2026 02:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Maravai Lifesciences Holdings, Inc. Class A \u2013 SWB:MAR", "summary": "This page displays the \"Price to earnings forward\" metric for Maravai Lifesciences Holdings, Inc. Class A, traded on the Stuttgart Stock Exchange under the symbol MAR. The primary content consists of various navigation links and footer information from the TradingView platform, w", "url": "https://www.tradingview.com/symbols/SWB-MAR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:12:23", "published_display": "29 Jun 2026 03:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MAR Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Maravai Lifesciences Holdings, Inc. (MAR) stock for 2027, based on analyst opinions. It details the company's financial performance, including recent earnings and revenue, and addresses frequently asked questions about its sto", "url": "https://www.tradingview.com/symbols/SWB-MAR/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T00:09:07", "published_display": "27 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai Lifesciences Holdings, Inc. Class A Actuals & Estimates (NASDAQ:MRVI)", "summary": "This article provides key financial metrics and analyst forecasts for Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI). It details the company's stock performance, market capitalization, earnings, revenue, and other financial data, highlighting recent fluctuations and future es", "url": "https://www.tradingview.com/symbols/NASDAQ-MRVI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T00:39:56", "published_display": "26 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium (MRVI) reports 7.32M shared stake, 4.96% as of Jun 16, 2026", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander filed a Schedule 13G for Maravai LifeSciences Holdings, Inc. (MRVI). The filing indicates shared beneficial ownership of 7,323,520 Class A common shares, representing 4.96% as of June 16, 2026. Al", "url": "https://www.stocktitan.net/sec-filings/MRVI/schedule-13g-maravai-lifesciences-holdings-inc-passive-investment-dis-44d9a9aeaeb1.html", "source_name": "Stock Titan", "published_at": "2026-06-23T22:52:31", "published_display": "23 Jun 2026 22:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (MRVI) Holds Steady as Shares Consolidate Near Support Levels - Fibonacci Retracement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPdmlkY3JJTEFKUTZnQk1Mc1N2MVZTQ0xKakdYMVdmWnNYUVRROHZHYmEzY2VNcmRrQ2xCYW0xa2RhdkI3bjFKMlozaTBGdzk0OTQ4cGRuUDJRXzdXZlVpVzVoS1ZFcUhfT3FQblYzVW1HeTVoTTVEbDZsdXR4c2tybEdKVkV0dzZZSXRHOUxCcXVaaGx6OFd4TWdBRXRlNFdhQlM5YWpWS1VGdTU2SVdoeGxheHNtMlRTNHFEWERTVXpzUQ?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-19T07:00:00+00:00", "published_display": "19 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai Lifesciences Unit TriLink Opens Enzyme Manufacturing Facility in Florida", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/maravai-lifesciences-unit-trilink-opens-140710740.html", "source_name": "MT Newswires", "published_at": "2026-06-16T14:07:10+00:00", "published_display": "16 Jun 2026 14:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences general counsel Oreshack sells $253,999 shares", "summary": "Kurt Oreshack, General Counsel at Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), recently sold 50,000 shares of the company's Class A Common Stock for approximately $253,999. These sales were conducted under a Rule 10b5-1 trading plan and occurred on June 9 and 10, 2026, with", "url": "https://m.uk.investing.com/news/insider-trading-news/maravai-lifesciences-general-counsel-oreshack-sells-253999-shares-93CH-4722722?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-11T00:10:27", "published_display": "11 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai Lifesciences Holdings Insider Sold Shares Worth $254,000, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/maravai-lifesciences-holdings-insider-sold-211654257.html", "source_name": "MT Newswires", "published_at": "2026-06-10T21:16:54+00:00", "published_display": "10 Jun 2026 21:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai Lifesciences director gifts 92,586 shares | MRVI Insider Trading", "summary": "Maravai Lifesciences Holdings director Gregory T. Lucier reported gifting 92,586 shares of Class A common stock on June 9, 2026. The gifts were made in two bona fide transfers of 46,293 shares each at $0.00 per share. Following these transactions, Lucier directly holds 155,123 sh", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-9a04c286903c.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:27", "published_display": "10 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (NASDAQ: MRVI) General Counsel sells 50,000 shares under 10b5-1 plan", "summary": "Maravai Lifesciences' General Counsel, Kurt Oreshack, sold a total of 50,000 shares of Class A Common Stock through open-market transactions on June 9 and June 10, 2026. These sales, totaling $254,000, were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 1", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-a398504aade9.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:27", "published_display": "10 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MRVI SEC Filings - Maravai Lifesciences Holdings, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides a comprehensive resource for Maravai Lifesciences Holdings (MRVI) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms. Recent filings detail director equity awards, a CFO transition, an", "url": "https://www.stocktitan.net/sec-filings/MRVI/page-5.html", "source_name": "Stock Titan", "published_at": "2026-06-10T21:10:21", "published_display": "10 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kurt Oreshack notifies sale of 25,000 MRVI Class A shares (NASDAQ: MRVI)", "summary": "Kurt Oreshack has filed a Form 144 to sell 25,000 Class A shares of Maravai Lifesciences Holdings, Inc. (MRVI). The filing, dated June 10, 2026, indicates an aggregate amount of $127,500.00 and notes that the securities originated from Restricted Stock Vesting on January 15, 2025", "url": "https://www.stocktitan.net/sec-filings/MRVI/144-maravai-lifesciences-holdings-inc-sec-filing-ad1cf470b617.html", "source_name": "Stock Titan", "published_at": "2026-06-10T19:39:59", "published_display": "10 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) brokered sale notice: 25,000 Class A shares via Fidelity", "summary": "Maravai LifeSciences (MRVI) has filed a Form 144, indicating an intent to sell 25,000 Class A common shares through Fidelity Brokerage Services LLC on NASDAQ. The filing details previous acquisitions of these shares through restricted stock vesting and ESPP purchases. This is a r", "url": "https://www.stocktitan.net/sec-filings/MRVI/144-maravai-lifesciences-holdings-inc-sec-filing-e5fd5a4cfd4a.html", "source_name": "Stock Titan", "published_at": "2026-06-09T14:39:38", "published_display": "09 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOdUV6ZnRYMFJSazNYZGVaOEtxOF9rb0djQ0xfU0FfLW9PY0pQYXFHdGJsbTBQVkNiMk45d3ZfT1dXdDBfekxCLWNCckxEMkMxRVltU0w5TW01T0FOVjFGQjBCQlhybm5UTlJCaXREbGFNeWYxamE4NDRsN2s5VDc4a0x3ZEV2SUpyLVVCU1NFWHE3bUl6VmZvUmxpQ2dmUEpEQTJ6Yw?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Refinances Credit Agreement, Extends Maturity to 2032", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/maravai-lifesciences-refinances-credit-agreement-130223268.html", "source_name": "MT Newswires", "published_at": "2026-06-03T13:02:23+00:00", "published_display": "03 Jun 2026 13:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/maravai-lifesciences-announces-refinancing-credit-123000426.html", "source_name": "Business Wire", "published_at": "2026-06-03T12:30:00+00:00", "published_display": "03 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (MRVI) Secures New $150M Credit Facility", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdkFnNXJyUmw5cmw3MWU5Z1JaMUc1MmxoOF8tVmNmd2QwOVVEWlRPYmxULUdUbHhfNXFNYzRrSW1LdzNsVVRQOTJycjZzYWxFSVhNdDR4ZVJIck1XaFd4TGxfM25jX2N3bU4wc1JMTEZjZ3hSd3FvaW40eGhERUdOdG1yYjJWOHh2ZUFhTXlkYTJ3X3FtT3d4c0JhNW11ZHBGVVhrX1h0WUJ5ZlZEWnc?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (MRVI) shareholders approve directors, auditor and pay at 2026 meeting", "summary": "Maravai LifeSciences Holdings, Inc. announced the results of its 2026 Annual Meeting of Shareholders. During the meeting, shareholders elected three directors to three-year terms, ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026, and ap", "url": "https://www.stocktitan.net/sec-filings/MRVI/8-k-maravai-lifesciences-holdings-inc-reports-material-event-188be1450a75.html", "source_name": "Stock Titan", "published_at": "2026-05-29T20:39:30", "published_display": "29 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) director granted 46,293 restricted stock units", "summary": "Maravai LifeSciences Holdings director Gregory T. Lucier was granted 46,293 restricted stock units of Class A Common Stock on May 26, 2026, with a grant price of $0.00. This award, under the 2020 Omnibus Incentive Plan, vests in full on the earlier of one year from the grant date", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-a-maravai-lifesciences-holdings-inc-amended-insider-trading-ac-c1d9ba1afff0.html", "source_name": "Stock Titan", "published_at": "2026-05-29T00:39:31", "published_display": "29 May 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) director Susannah Gray receives 46,293-share stock unit award", "summary": "Maravai LifeSciences Holdings, Inc. director Susannah Gray was granted 46,293 restricted stock units (RSUs) of Class A Common Stock. This award, made under the 2020 Omnibus Incentive Plan, increased her direct holdings to 216,200 shares. The RSUs will vest in full after one year ", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-6847ba982f28.html", "source_name": "Stock Titan", "published_at": "2026-05-28T22:10:56", "published_display": "28 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] MARAVAI LIFESCIENCES HOLDINGS, INC. Insider Trading Activity", "summary": "Maravai LifeSciences (MRVI) director Gregory T. Lucier reported an acquisition of 46,293 shares of Class A Common Stock through restricted stock units (RSUs) at a reference price of $4.38 per share. This RSU award, granted under the 2020 Omnibus Incentive Plan, vests fully on the", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-9deefc0707d3.html", "source_name": "Stock Titan", "published_at": "2026-05-28T22:10:56", "published_display": "28 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (MRVI) director receives 46,293-share RSU award", "summary": "MARAVAI LIFESCIENCES HOLDINGS, INC. director R. Andrew Eckert was granted 46,293 restricted stock units (RSUs) of Class A common stock as an equity compensation award on May 26, 2026. These RSUs were issued at no cost and will vest fully on the earlier of one year from the grant ", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-2bd4741c3ea9.html", "source_name": "Stock Titan", "published_at": "2026-05-28T22:10:56", "published_display": "28 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU grant to GTCR-affiliated entity via Maravai (MRVI) director", "summary": "Maravai LifeSciences Holdings director Sean Laurence Cunningham was awarded a 46,293-share Restricted Stock Unit (RSU) grant, vesting on the earlier of one year from May 26, 2026, or the company's 2027 annual meeting. These securities are held for the benefit of a GTCR-affiliated", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-bb371be12755.html", "source_name": "Stock Titan", "published_at": "2026-05-28T22:10:56", "published_display": "28 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) director Mihas receives 46,293 RSUs held for GTCR-affiliated entity", "summary": "Maravai LifeSciences Holdings, Inc. director Constantine S. Mihas was granted 46,293 restricted stock units (RSUs) of Class A common stock on May 26, 2026, under the company's 2020 Omnibus Incentive Plan. These RSUs vest fully on the earlier of one year from the grant date or the", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-d7bc09b75dd0.html", "source_name": "Stock Titan", "published_at": "2026-05-28T22:10:56", "published_display": "28 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) director awarded 46,293 RSUs in equity grant", "summary": "Maravai LifeSciences (MRVI) director John A. DeFord was granted 46,293 restricted stock units (RSUs) on May 26, 2026. These RSUs, awarded under the company\u2019s 2020 Omnibus Incentive Plan, will vest fully on the earlier of one year from the grant date or the 2027 annual stockholder", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-193dbde019f4.html", "source_name": "Stock Titan", "published_at": "2026-05-28T22:10:56", "published_display": "28 May 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai Lifesciences (NASDAQ: MRVI) counsel gets 776 ESPP shares", "summary": "Maravai LifeSciences Holdings, Inc.'s General Counsel, Kurt Oreshack, acquired 776 shares of Class A Common Stock at $2.84 per share through the company\u2019s 2020 Employee Stock Purchase Plan. This transaction, exempt under Rule 16b-3, increased Oreshack's direct holdings to 385,767", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-fcc6a30e595b.html", "source_name": "Stock Titan", "published_at": "2026-05-22T23:09:27", "published_display": "22 May 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) officer granted 5,006 ESPP shares at $1.79", "summary": "Maravai LifeSciences Holdings insider Christine Dolan acquired 5,006 shares of Class A common stock at $1.79 per share through the company's 2020 Employee Stock Purchase Plan. This transaction, exempt under Rule 16b-3, increases Dolan's direct holdings to 425,318 shares and is co", "url": "https://www.stocktitan.net/sec-filings/MRVI/form-4-maravai-lifesciences-holdings-inc-insider-trading-activity-1c6b8dd8d00d.html", "source_name": "Stock Titan", "published_at": "2026-05-22T23:09:27", "published_display": "22 May 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQYzh6Tmw3VHNoNk5Xelg1Sk1rNmRpQnVTbm96Wm43UjBWTENqQTdYR1F6bFMtbWhvOWl2alV1cFdJSXFYVTVmZ29JSkFmc0dfQmpHWnpVdHE5OFlUejRwblJ6Vl9wT0N2V3IyejdOS2RXbXVyYzd2aG95VWdsaVFHZDFsNkJHT2VQMF9tV1RhY2llQklGaTlkLW55R24zQV8yWl9TSnFRR2twVjJhYlZIOXdZWnpzb1luMkE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Q1 Turnaround Spurs Rethink Of CleanCap Driven Outlook", "summary": "Maravai LifeSciences Holdings (NasdaqGS:MRVI) reported a significant Q1 2026 turnaround with a 41% revenue jump, narrowed net loss, and positive Adjusted EBITDA, driven by a large CleanCap vaccine order and debt reduction. The strong performance has led to a re-evaluation of the ", "url": "https://www.sahmcapital.com/news/content/maravai-lifesciences-q1-turnaround-spurs-rethink-of-cleancap-driven-outlook-2026-05-14", "source_name": "Sahm", "published_at": "2026-05-15T19:10:09", "published_display": "15 May 2026 19:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 West Capital Amends 13G, Holds 7.26M Shares in Maravai (MRVI)", "summary": "12 West Capital Management and Joel Ramin have filed an amended 13G, reporting beneficial ownership of 7,260,195 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI), which represents a 4.9% stake in the company. This percentage is calculated based on 146,383", "url": "https://www.stocktitan.net/sec-filings/MRVI/schedule-13g-a-maravai-lifesciences-holdings-inc-amended-passive-inve-a778da77a7e3.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:40:04", "published_display": "15 May 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 Guidance", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/maravai-lifesciences-mrvi-narrative-shifting-012919067.html", "source_name": "Simply Wall St.", "published_at": "2026-05-15T01:29:19+00:00", "published_display": "15 May 2026 01:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stuart Feldman-led group reports 9.21% stake in Maravai (MRVI)", "summary": "A group led by Stuart Feldman has filed an amended Schedule 13G/A, disclosing a passive beneficial ownership of 13,488,799 shares of Maravai LifeSciences Holdings, Inc. Class A common stock, representing 9.21% of the class. Stuart Feldman individually holds 10,337,680 shares (7.0", "url": "https://www.stocktitan.net/sec-filings/MRVI/schedule-13g-a-maravai-lifesciences-holdings-inc-amended-passive-inve-b5a0edde9804.html", "source_name": "Stock Titan", "published_at": "2026-05-14T20:40:02", "published_display": "14 May 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium group lists 4.9% holding in Maravai (NASDAQ: MRVI) on 13G", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G reporting a shared voting and dispositive power over 7,228,864 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock, which represents a 4.9% stake. The fili", "url": "https://www.stocktitan.net/sec-filings/MRVI/schedule-13g-maravai-lifesciences-holdings-inc-passive-investment-dis-2c343564da89.html", "source_name": "Stock Titan", "published_at": "2026-05-13T05:40:49", "published_display": "13 May 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai (MRVI) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/9ce5ab11-8fd7-3ac3-b423-d589e116c563/maravai-%28mrvi%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-09T20:35:31+00:00", "published_display": "09 May 2026 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (NASDAQ: MRVI) boosts Q1 revenue, cuts debt", "summary": "Maravai LifeSciences reported significantly improved financial results for Q1 2026, with revenue increasing by 40.5% to $65.8 million, driven largely by its TriLink segment and $14.3 million in CleanCap\u00ae COVID-19 vaccine orders. The net loss narrowed to $6.4 million, and Adjusted", "url": "https://www.stocktitan.net/sec-filings/MRVI/10-q-maravai-lifesciences-holdings-inc-quarterly-earnings-report-2721b0d7cbe9.html", "source_name": "Stock Titan", "published_at": "2026-05-09T18:09:14", "published_display": "09 May 2026 18:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Holdings, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/c1ba3b95-75ec-390b-925d-7c3e9c5e00f3/maravai-lifesciences.html", "source_name": "Moby", "published_at": "2026-05-08T12:30:00+00:00", "published_display": "08 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deutsche Bank Adjusts Maravai Lifesciences Price Target to $6 From $4.50, Maintains Buy Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/deutsche-bank-adjusts-maravai-lifesciences-122255168.html", "source_name": "MT Newswires", "published_at": "2026-05-08T12:22:55+00:00", "published_display": "08 May 2026 12:22", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Holdings, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:MRVI) 2026-05-07", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaklXcE4wYUs2UWJzUGZEcUZtZ3hFQUl4RWlGMkF1NVJoM1dHWEtDMDhEcnF2RGVaYzRvMjk4NzZhOGZkenBXbVVQdXo3Tm5RRUdvLUlDOWRCOEp6MXlocEtCRnZmMjdoZzFkcUg2QVZqTkFTakJQczNSdXhzbWJwWmR5M3hvdzQ0WGtFSTl0SzRTRlhSeTBmVkpBUDFFWk0tUzBpTERzWXFJNXhNc19QdGx2ZEJSZ0RF?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWEp3YzZMemQ3bkFBSkZOdW1oc18tUEJrV21GUzBURmNIcWdQVHp1cnJkYWpQdE1ndEFtRnMyU3NYbThBSE1XZWNYZGw5emdtUXdjMG5QY3pqMjBiT3JPQTBWRjBwOEc5MXF4SW5EQm91R3UweEdlY1dPdG84LWM1Vi1STU11UVhXRnc2eVFWdm1LU2dPZDRfc19PZmFZM29yZjNFbFJLMmlaYmM?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxORzBTYmpmaVo5Ri0zWjZGX21zN3F2N3lTVXBDNnp5cVJuTlJoM3YwSUVCNEZkWVhJU0VDS1NJcXp3dTYzNUhfUElXeVNZakxiWFVwZVZZOGNFM2prZVBIU1Q5ZFNSQTZEWXJocXNKNU1weHhpOEVoV1AzYVoyS2h3Z3dYM2xqcC14eXBDQmpPcU9rUDR1ejRhWmlEbGNLcDJlYUZYMA?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences (MRVI) Carrying Moderately Bullish Sentiment Despite Options-Linked Volatility", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQQ2hNaHVESGlacDkyRzI5SkRfZ2VreDd5dWJZV3Mwc09mVW8wNGttNEtkeGRjZm9GRXE2MklpUU44MFlGaVEzOGV5SEVKeFQ5RVpoQ2FIdXJNVEpGVk5FLWphT0E5Y2wyWG5HQ1ZITjZvNHdxNUxWMVVuSV9lTEg5bTVmaFlKemlaR2JiX29Nc2hsNUFtYjFQX2E5WFRvR3lnclFsS3ZOYVBxdTJ1eXFV?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Maravai LifeSciences (MRVI) Story Is Shifting As Analysts Rework Fair Value Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNcFBCcW9XZ0tveU1xbnZoam8tcmhjQjRzR2VnRGtEUEhVVk5hSDR6Y191MlRJbUYtUXNPWW5ZUlhDZ25ITEpyaUpPdDNCaHczeU9KdWxXTWdvRHVibFZ5ekQzRUVvaFNfdmlEYUVWWm95dXc3Z0hrSkhtcGFJMm5rbjlPeVB6d1c1bUh3c3BmS0drLXFjYy1DTEJEb3ZRRHlhR1l3REFPOWo?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maravai LifeSciences Holdings (NASDAQ:MRVI shareholders incur further losses as stock declines 11% this week, taking five-year losses to 90%", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxOQ2taSnc5Vmc5N2ZkZnM0TkowUVFBRzUtTDhPLXRBeDV0cjdZVnYzQUcydnpZNG5LbmlRZnRoV0FDWlZDdm1Qa01GbHFPRUdLRThXVE9HNEIyb3NsSGxWeWNKcnByR2U1SDNCWmVaRVY2UEtzMlBBVzJaT3ZOcHlPcFZkM21GRGJaaG9ISXp3OEVKUHo2TjlvTHhoZzk0OEwwUTQ3cHBuTVBSaC1idDBDNXB1cW85REtLRFQyTWtGUDk2dW5jZDRJbm1uNHRQVFJoWV9pY2dkUUptZ0pnQl9BSlp1TVlLLXduem5WNVB0RjBJSHJa0gH6AUFVX3lxTE5UOXd4U1hrSVA4SWV6TWFtdmNLNlJoZnRtR0xoN2Y2OHg5Nlp2dGRTMWx2ajdKb2hxYUVOdkVzYXRsMThzd2I3SW1FazQyUUs5NU5udjFWTnNQcnFfRmRqUVYzdVdVTUEzUDVhakNvRVF5WW5qMWFKeXkzczBfOF9MZ3lHb2VpNTVYams5eFNkUEt5V3NEbnRUajhpanMxRlJUNnFDZHdtbjlTcTVUWkpUSEhFdkFLcjdnZ2VUV0JvazVNQUgwTWlEeXNQNjZRaFAwMEZmbGF1Qy1WWHZJa2pueGd6N3A3TC1ZZjNtWmtnSnh5U3AyUFJDbHc?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Maravai LifeSciences Holdings (NASDAQ:MRVI) Using Too Much Debt?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-15T08:00:00+00:00", "published_display": "15 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 62, "sentiment_summary": {"positive": 8, "negative": 3, "neutral": 51, "score": 51, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 10.6, "count": 20}, {"event": "deals", "label": "Deals and strategy", "weight": 3.85, "count": 7}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 6.09, "latest_week": "2026-07-10", "one_week_move": 0.8, "four_week_move": 22.3, "twelve_week_move": 79.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.484438, "market_dynamics_buy_signal": false, "relative_strength": 50.202678, "fair_value_gap": 9.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.0057, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.8% over one week, +22.3% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 48, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 23}, {"label": "Market source", "count": 10}, {"label": "TradingView", "count": 6}, {"label": "MT Newswires", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Seeking Alpha", "count": 2}, {"label": "Moomoo", "count": 1}, {"label": "Investing.com Nigeria", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 20}, {"label": "Deals and strategy", "count": 7}, {"label": "Balance sheet", "count": 4}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.8% over one week, +22.3% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Maravai LifeSciences(MRVI) Stock Options Chain | Quotes & News"}], "updated_at": "2026-07-16T05:41:26.479417+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}